Safety of calcium and vitamin D supplements, a randomized controlled trial
Safety of calcium and vitamin D supplements, a randomized controlled trial
复制标题
DOI：
10.1111/cen.13848
复制
发表时间：
2018-12-01
影响因子：
3.2
通讯作者：
Islam, Shahidul
中科院分区：
文献类型：
--
作者：
Aloia, John F.;Katumuluwa, Subhashini;Islam, Shahidul
目的根据内分泌学会指南，维生素D摄入量（10 000 IU/d）与钙补充剂联合使用可能会导致频繁的高钙尿症和高钙血症。这种组合可能与肾结石有关。本研究的目的是比较钙补充剂与10 000 IU或600 IU维生素D每日联合给药引起的高钙尿症和高钙血症的发作。该设计允许将医学研究所推荐的维生素D的RDA沿着钙摄入量的上限与内分泌学会建议的维生素D的高摄入量进行比较。目前推荐的高维生素D摄入量的危害尚未研究。设计设计为随机对照试验，分为2组，每3个月进行一年的评估：（a）CaCO 3 1200 mg/天，10 000 IU维生素D-3/天或（B）CaCO 3 1200 mg/天，600 IU维生素D-3/天。患者本研究在门诊研究中心的健康绝经后白色女性中进行。测量血清和24小时尿钙。结果两组均出现高钙血症和高钙尿症。在末次访视时，高剂量D组中19/48例出现高钙尿症。高剂量D组发生高钙尿症的几率高3.6 [OR = 3.6（1.39，9.3）]倍。发生高钙血症的几率在两组之间没有差异。结论：内分泌学会推荐的维生素D安全上限水平与钙补充剂同时使用时，会导致频繁的高钙尿症。肾结石的风险在这些水平应进行调查。
Objective It is anticipated that an intake of vitamin D found acceptable by Endocrine Society Guidelines (10 000 IU/day) with co-administered calcium supplements may result in frequent hypercalciuria and hypercalcaemia. This combination may be associated with kidney stones. The objective of this study was to compare the episodes of hypercalciuria and hypercalcaemia from calcium supplements co-administered with 10 000 IU or 600 IU vitamin D daily. This design allows a comparison of the Institute of Medicine recommendation for the RDA of vitamin D along with the upper limit of calcium intake with the high intake of vitamin D suggested by the Endocrine Society. Context Harms of currently recommended high intake of vitamin D have not been studied. Design The design was a randomized controlled trial with 2 groups with evaluation every 3 months for one year: (a) CaCO3 1200 mg/day with 10 000 IU vitamin D-3/day or (b) CaCO3 1200 mg/day with 600 IU vitamin D-3/day. Patients This study was conducted in an ambulatory research centre in healthy, white postmenopausal women. Measurements Serum and 24-hour urine calcium were measured. Results Hypercalcaemia and hypercalciuria occurred in both groups. At the final visit, 19/48 in the high dose D group had hypercalciuria. The odds of developing hypercalciuria were 3.6 [OR = 3.6(1.39, 9.3)] times higher in the high dose D group. The odds of developing hypercalcaemia did not differ between groups. Conclusions The safe upper level of vitamin D recommended by the Endocrine Society when accompanied by calcium supplements results in frequent hypercalciuria. The risk of kidney stones at these levels should be investigated.